Ebglyss is a medicine used to treat moderate to severe atopic dermatitis (also known as atopic eczema, when the skin is itchy, red and dry). It is used in adults and children aged 12 years and over weighing at least 40 kg. It is used in patients for whom treatment applied directly to the skin cannot be used or is not sufficient. Ebglyss contains the active substance lebrikizumab.
Therapeutic Indication
### Therapeutic indication Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.
Therapeutic Area (MeSH)
ATC Code
D11AH10
ATC Item
lebrikizumab
Pharmacotherapeutic Group
Other dermatological preparations
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Lebrikizumab | N/A | Lebrikizumab |
EMA Name
Ebglyss
Medicine Name
Ebglyss
Aliases
N/A
